Your browser doesn't support javascript.
loading
Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer.
Dieter, Sebastian M; Siegl, Christine; Codó, Paula L; Huerta, Mario; Ostermann-Parucha, Anna L; Schulz, Erik; Zowada, Martina K; Martin, Sylvia; Laaber, Karin; Nowrouzi, Ali; Blatter, Mona; Kreth, Sina; Westermann, Frank; Benner, Axel; Uhrig, Ulrike; Putzker, Kerstin; Lewis, Joe; Haegebarth, Andrea; Mumberg, Dominik; Holton, Simon J; Weiske, Joerg; Toepper, Lena-Marit; Scheib, Ulrike; Siemeister, Gerhard; Ball, Claudia R; Kuster, Bernhard; Stoehr, Gabriele; Hahne, Hannes; Johannes, Sarah; Lange, Martin; Herbst, Friederike; Glimm, Hanno.
Afiliação
  • Dieter SM; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Dresden and German Cancer Research Center (DKFZ), 01307 Dresden, Germany; Translational Functional Cancer Genomics, NCT and DKFZ Heidelberg, 69120 Heidelberg, Germany. Electronic address: sebastian.dieter@nct-heid
  • Siegl C; Merck KGaA, 64293 Darmstadt, Germany.
  • Codó PL; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Dresden and German Cancer Research Center (DKFZ), 01307 Dresden, Germany; Translational Functional Cancer Genomics, NCT and DKFZ Heidelberg, 69120 Heidelberg, Germany; CureVac AG, 60325 Frankfurt am Main, Germany.
  • Huerta M; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Dresden and German Cancer Research Center (DKFZ), 01307 Dresden, Germany; Translational Functional Cancer Genomics, NCT and DKFZ Heidelberg, 69120 Heidelberg, Germany.
  • Ostermann-Parucha AL; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Dresden and German Cancer Research Center (DKFZ), 01307 Dresden, Germany; Translational Functional Cancer Genomics, NCT and DKFZ Heidelberg, 69120 Heidelberg, Germany.
  • Schulz E; Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, 69120 Heidelberg, Germany.
  • Zowada MK; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Dresden and German Cancer Research Center (DKFZ), 01307 Dresden, Germany; Translational Functional Cancer Genomics, NCT and DKFZ Heidelberg, 69120 Heidelberg, Germany; Faculty of Biosciences, Heidelberg University
  • Martin S; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Dresden and German Cancer Research Center (DKFZ), 01307 Dresden, Germany; Translational Functional Cancer Genomics, NCT and DKFZ Heidelberg, 69120 Heidelberg, Germany.
  • Laaber K; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Dresden and German Cancer Research Center (DKFZ), 01307 Dresden, Germany; Translational Functional Cancer Genomics, NCT and DKFZ Heidelberg, 69120 Heidelberg, Germany; Faculty of Biosciences, Heidelberg University
  • Nowrouzi A; Division of Molecular and Translational Radiation Oncology, Heidelberg Medical Faculty, Heidelberg University, 69120 Heidelberg, Germany.
  • Blatter M; Hopp Children's Cancer Center Heidelberg (KiTZ), 69120 Heidelberg, Germany; Division of Neuroblastoma Genomics, DKFZ Heidelberg, 69120 Heidelberg, Germany.
  • Kreth S; Hopp Children's Cancer Center Heidelberg (KiTZ), 69120 Heidelberg, Germany; Division of Neuroblastoma Genomics, DKFZ Heidelberg, 69120 Heidelberg, Germany.
  • Westermann F; Hopp Children's Cancer Center Heidelberg (KiTZ), 69120 Heidelberg, Germany; Division of Neuroblastoma Genomics, DKFZ Heidelberg, 69120 Heidelberg, Germany.
  • Benner A; Division of Biostatistics, DKFZ Heidelberg, 69120 Heidelberg, Germany.
  • Uhrig U; European Molecular Biology Laboratory (EMBL), Chemical Biology Core Facility, 69117 Heidelberg, Germany.
  • Putzker K; European Molecular Biology Laboratory (EMBL), Chemical Biology Core Facility, 69117 Heidelberg, Germany.
  • Lewis J; European Molecular Biology Laboratory (EMBL), Chemical Biology Core Facility, 69117 Heidelberg, Germany.
  • Haegebarth A; Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany.
  • Mumberg D; Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany.
  • Holton SJ; Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany; Nuvisan Innovation Campus Berlin GmbH, 13353 Berlin, Germany.
  • Weiske J; Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany; Nuvisan Innovation Campus Berlin GmbH, 13353 Berlin, Germany.
  • Toepper LM; Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany; Nuvisan Innovation Campus Berlin GmbH, 13353 Berlin, Germany.
  • Scheib U; Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany; Nuvisan Innovation Campus Berlin GmbH, 13353 Berlin, Germany.
  • Siemeister G; Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany; Nuvisan Innovation Campus Berlin GmbH, 13353 Berlin, Germany.
  • Ball CR; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Dresden and German Cancer Research Center (DKFZ), 01307 Dresden, Germany; Translational Functional Cancer Genomics, NCT and DKFZ Heidelberg, 69120 Heidelberg, Germany; German Cancer Consortium (DKTK), 01307 Dresde
  • Kuster B; Chair of Proteomics and Bioanalytics, Technical University of Munich, 85354 Freising, Germany.
  • Stoehr G; OmicScouts GmbH, 85354 Freising, Germany.
  • Hahne H; OmicScouts GmbH, 85354 Freising, Germany.
  • Johannes S; Bayer AG, Research & Development, Pharmaceuticals, 42117 Wuppertal, Germany.
  • Lange M; Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany; Nuvisan Innovation Campus Berlin GmbH, 13353 Berlin, Germany.
  • Herbst F; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Dresden and German Cancer Research Center (DKFZ), 01307 Dresden, Germany; Translational Functional Cancer Genomics, NCT and DKFZ Heidelberg, 69120 Heidelberg, Germany.
  • Glimm H; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Dresden and German Cancer Research Center (DKFZ), 01307 Dresden, Germany; Translational Functional Cancer Genomics, NCT and DKFZ Heidelberg, 69120 Heidelberg, Germany; German Cancer Consortium (DKTK), 01307 Dresde
Cell Rep ; 36(3): 109394, 2021 07 20.
Article em En | MEDLINE | ID: mdl-34289372
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Ciclinas / Quinases Ciclina-Dependentes / Proteólise / Antineoplásicos Limite: Female / Humans Idioma: En Revista: Cell Rep Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Ciclinas / Quinases Ciclina-Dependentes / Proteólise / Antineoplásicos Limite: Female / Humans Idioma: En Revista: Cell Rep Ano de publicação: 2021 Tipo de documento: Article